orforglipron semaglutide comparison Orglipron outperforms Farxiga in diabetes trials, offers oral alternative | Anil Kumar Laxman posted on the topic obesity #diabetes #endocrinology #glp1 #obesitytreatment
Description
Tirzepatide (15mg, Zepbound): Up to 22.5% body weight reduction over 72 weeks in the SURMOUNT trials
It activates the GLP-1 and GIP receptors in your body
Early winners sold access
Who Benefits Most from Microdosing GLP-1
Can you reach a real person
References Campbell JE, Muller TD, Finan B, DiMarchi RD, Tschop MH, DAlessio DA
